Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95452
UPID:
CXB6_HUMAN
Alternative names:
Connexin-30
Alternative UPACC:
O95452; B3KQN2; Q5Q1H9; Q5Q1I0; Q5Q1I1; Q5T5U0; Q8IUP0
Background:
Gap junction beta-6 protein, also known as Connexin-30, plays a pivotal role in cell communication. It forms gap junctions, facilitating the diffusion of low molecular weight materials between cells. This protein's structure and function are crucial for maintaining cellular homeostasis and supporting tissue function.
Therapeutic significance:
Connexin-30 is implicated in Ectodermal dysplasia 2, Clouston type, and various forms of sensorineural hearing loss. Its involvement in these conditions highlights its potential as a target for therapeutic intervention, aiming to alleviate symptoms or possibly cure these diseases.